Why Better Life Science’s Lyme testing push matters more for access than for diagnosis alone
Better Life Science is pushing at-home Lyme testing this spring. Read what Tick Bite Hero changes, where it fits, and what risks remain.
Can Abbisko Therapeutics turn irpagratinib into the first approved FGFR4 therapy for hepatocellular carcinoma?
Abbisko Therapeutics won EMA orphan drug designation for irpagratinib in liver cancer. Read what this changes for FGFR4-targeted therapy.
Can Tenpoint Therapeutics’ direct-to-patient YUVEZZI program unlock wider access in the presbyopia market?
Tenpoint Therapeutics and PHIL launch YUVEZZI direct-to-patient access for presbyopia. Read what it means for affordability, uptake, and market adoption.
Can EarliPoint Health and Netsmart reduce autism diagnosis bottlenecks in provider settings?
EarliPoint Health and Netsmart are expanding access to autism assessment technology. Read what this could change for providers, workflows, and adoption.
PharmaEssentia expands beyond Taiwan with Puerto Rico plant as BESREMi growth plans widen
PharmaEssentia’s Puerto Rico facility could reshape BESREMi supply resilience and U.S. expansion. Read what this means for biologics strategy.
Why CTIS is betting FDA’s E2B(R3) deadline will reshape pharmacovigilance software demand;
CTIS launches Trial SafetyXchange to help pharma firms meet the FDA E2B(R3) deadline. Read what it changes for safety reporting teams.
Can Aspect Biosystems turn government-backed biomanufacturing into a real regenerative medicine advantage?
Aspect Biosystems has secured a $280 million Canada-backed push in regenerative medicine. Read what it means for cellular therapy scale-up.
OpenEvidence expands beyond search as Tandem partnership pushes medical AI into prescription access workflows
OpenEvidence and Tandem are linking clinical AI with prior authorization automation. Read what this could change for prescribing, access, and workflow.
Can VR LIFE and H2 Global Group turn European MedTech validation into real global scale?
Can VR LIFE and H2 Global Group scale from European validation to global MedTech relevance? Read the deeper analysis now.
Can Allevion Medical’s Vantage change spinal stenosis workflows by combining disposable access, illumination, and bone resection tools?
Allevion Medical’s Vantage won FDA 510(k) clearance for lumbar decompression. Read what this may change for spinal stenosis workflow, adoption, and risk.